Central lab support for HPV and cervical cancer prevention in people living with HIV
CAMPO Central Laboratory Core
['FUNDING_OTHER'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11399231
This project runs the lab testing that supports three clinical efforts to prevent and treat cervical and anal precancers and HPV infections in people living with HIV in Mexico and Puerto Rico.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11399231 on ClinicalTrials.gov |
What this research studies
From a patient's point of view, this effort provides the laboratory testing for three linked clinical efforts focused on preventing cervical cancer among people with HIV. One component looks at new screening approaches for cervical precancer in 4,000 HIV-positive women, another tests whether anogenital probiotics change the anal and cervical microbiome and help lesions go away in about 600 HIV-positive women and men, and a third tests a multivalent adenovirus-based therapeutic HPV vaccine in 300 HIV-positive women and men. The central laboratory runs the assays needed for the main study goals and for correlative science, working with data and clinical cores. The core also aims to build lab capacity for partner sites in Mexico and Puerto Rico.
Who could benefit from this research
Good fit: Ideal candidates are people living with HIV—particularly women for the cervical screening component and both women and men with anal or cervical HSIL or high-risk HPV at CAMPO consortium sites in Mexico and Puerto Rico.
Not a fit: People who are HIV-negative, who do not have HPV or HSIL, or who cannot attend participating sites in Mexico or Puerto Rico would not be eligible or likely to benefit directly.
Why it matters
Potential benefit: If successful, this work could improve how cervical and anal precancers are detected and treated in people living with HIV and could lead to new microbiome or vaccine-based treatments.
How similar studies have performed: Related screening strategies and HPV-directed therapies have shown promise in some settings, but therapeutic HPV vaccines and microbiome-based treatments remain early and incompletely proven.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DARRAGH, TERESA MARIE — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: DARRAGH, TERESA MARIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, Cancers